Company intelligence / Profile preview

VegaVect

Pittsburgh, Pennsylvania, United Statesvegavecttx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

VegaVect is conducting a Phase 1/2 clinical trial for X-linked Retinoschisis using intravitreal gene replacement therapy with AAV8-scRS-IRBP-hRS (NCT02317887). The trial was initially started at the National Eye Institute, NIH, but was paused due to COVID-19 and is now being continued by VegaVect.

Therapeutic areas: Ophthalmology
Modalities: Gene therapyAAV vectors
Industry: Biotech

Drug pipeline

1 asset

RS1 gene therapy

Phase 1/2

Indications: X-linked Retinoschisis

Partnerships

National Eye Institute, NIH

Beyond the preview

Go deeper on VegaVect.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VegaVect.

Explore the full profile